Abstract:Protein homeostasis (proteostasis) requires the timely degradation of misfolded proteins and their aggregates by protein quality control (PQC), of which molecular chaperones are an essential component. Compared with other cell types, PQC in neurons is particularly challenging because they have a unique cellular structure with long extensions. Making it worse, neurons are postmitotic, i.e., cannot dilute toxic substances by division, and, thus, are highly sensitive to misfolded proteins, especially as they age. Failure in PQC is often associated with neurodegenerative diseases, such as Huntington's disease (HD), Alzheimer's disease (AD), Parkinson's disease (PD), and prion disease. In fact, many neurodegenerative diseases are considered to be protein misfolding disorders. To prevent the accumulation of disease-causing aggregates, neurons utilize a repertoire of chaperones that recognize misfolded proteins through exposed hydrophobic surfaces and assist their refolding. If such an effort fails, chaperones can facilitate the degradation of terminally misfolded proteins through either the ubiquitin (Ub)-proteasome system (UPS) or the autophagy-lysosome system (hereafter autophagy). If soluble, the substrates associated with chaperones, such as Hsp70, are ubiquitinated by Ub ligases and degraded through the proteasome complex. Some misfolded proteins carrying the KFERQ motif are recognized by the chaperone Hsc70 and delivered to the lysosomal lumen through a process called, chaperone-mediated autophagy (CMA). Aggregation-prone misfolded proteins that remain unprocessed are directed to macroautophagy in which cargoes are collected by adaptors, such as p62/SQSTM-1/Sequestosome-1, and delivered to the autophagosome for lysosomal degradation. The aggregates that have survived all these refolding/degradative processes can still be directly dissolved, i.e., disaggregated by chaperones. Studies have shown that molecular chaperones alleviate the pathogenic symptoms by neurodegeneration-causing protein aggregates. Chaperone-inducing drugs and anti-aggregation drugs are actively exploited for beneficial effects on symptoms of disease. Here, we discuss how chaperones protect misfolded proteins from aggregation and mediate the degradation of terminally misfolded proteins in collaboration with cellular degradative machinery. The topics also include therapeutic approaches to improve the expression and turnover of molecular chaperones and to develop anti-aggregation drugs.

DNAJ Proteins in neurodegeneration: essential and protective factors

The roles of HSP40/DNAJ protein family in neurodegenerative diseases

DnaJC7 in Amyotrophic Lateral Sclerosis

DNA Damage and Chromatin Rearrangement Work Together to Promote Neurodegeneration

The Role of Co-chaperones in Synaptic Proteostasis and Neurodegenerative Disease

Proteins Associated with Neurodegenerative Diseases: Link to DNA Repair

The ALS-associated co-chaperone DNAJC7 mediates neuroprotection against proteotoxic stress by modulating HSF1 activity

Molecular Chaperones: A Double-Edged Sword in Neurodegenerative Diseases

Differential roles for DNAJ isoforms in HTT-polyQ and FUS aggregation modulation revealed by chaperone screens

The Nuclear and DNA-Associated Molecular Chaperone Network

DNAJC proteins and pathways to parkinsonism

Protein Quality Control by Molecular Chaperones in Neurodegeneration

Heat Shock Protein 90 in Neurodegenerative Diseases

Molecular chaperones biochemistry and role in neurodegenerative diseases

In vivo suppression of polyglutamine aggregation via co-condensation of the molecular chaperone DNAJB6

The HSP40 family chaperone isoform DNAJB6b prevents neuronal cells from tau aggregation

Molecular chaperones as modulators of polyglutamine protein aggregation and toxicity

The co-chaperone DNAJA2 buffers proteasomal degradation of cytosolic proteins with missense mutations

Small Heat Shock Proteins, Big Impact on Protein Aggregation in Neurodegenerative Disease

Polyglutamine Expansion in Huntingtin and Mechanism of DNA Damage Repair Defects in Huntington's Disease

Characterization of a Brain-enriched Chaperone, MRJ, That Inhibits Huntingtin Aggregation and Toxicity Independently